Implementation of methadone therapy for opioid use disorder in Russia – a modeled cost-effectiveness analysis
| Autor: | Sean M. Murphy, Mayada Saadoun, Donald S. Shepard, Tyler Morrill, Karsten Lunze, Bulat Idrisov |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Cost-Benefit Analysis Service coverage World health Russia 03 medical and health sciences 0302 clinical medicine Environmental health Russia HIV Opiate Substitution Treatment Medicine HIV treatment Humans 030212 general & internal medicine Psychiatry health care economics and organizations business.industry Health Policy Public health Research Opioid use disorder Cost-effectiveness analysis Health Care Costs medicine.disease Opioid-Related Disorders 3. Good health Psychiatry and Mental health Health psychology Drug dependence TB Models Economic Cohort Quality-Adjusted Life Years business 030217 neurology & neurosurgery Methadone medicine.drug |
| Zdroj: | Substance Abuse Treatment, Prevention, and Policy |
| ISSN: | 1747-597X |
| Popis: | Background Opioid agonist therapy using methadone, an effective treatment of opioid use disorders (OUD) for people who inject drugs (PWID), is recommended by the World Health Organization as essential to curtail the growing HIV epidemic. Yet, despite increasing prevalence of OUD and HIV, methadone therapy has not yet been implemented in Russia. The aim of this modeling study was to estimate the cost-effectiveness of methadone therapy for Russian adults with a diagnosed OUD. Methods/Design We modeled the projected program implementation costs and estimated disability-adjusted life years (DALYs) averted over a 10-year period, associated with the provision of methadone therapy for a hypothetical, unreplenished cohort of Russian adults with an OUD (n = 249,000), in comparison to the current therapies at existing addiction treatment facilities. Our model compared four distinct scenarios of treatment coverage in the cohort ranging from 3.1 to 55%. Results Providing methadone therapy to as few as 3.1% of adults with an OUD amounted to an estimated almost 50,000 DALYs averted over 10 years at a cost of just over USD 17 million. Further expanding service coverage to 55% resulted in an estimated almost 900,000 DALYs averted, at a cost of about USD 308 million. Conclusion Our study indicated that implementing opioid agonist therapy with methadone to treat OUD at existing facilities in Russia is highly cost-effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink